Case 23

Published on 03/03/2015 by admin

Filed under Neurology

Last modified 03/03/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1127 times

Case 23

HISTORY AND PHYSICAL EXAMINATION

Fever, malaise, and sore throat developed in a 55-year-old woman who was otherwise in excellent health. She was treated with antibiotics and analgesics. Six days later, she first noticed that her legs had “buckled” underneath her. That afternoon, she had difficulty climbing steps and became aware of tingling in both hands. She awoke the next morning and could not stand. She was brought to the hospital and was admitted. Apart from a diuretic for mild hypertension, she was taking no other medications.

On physical examination, the patient was afebrile and in no apparent distress. She had normal vital signs, including blood pressure, pulse, and respiration. Neurologic examination revealed normal mental status and cranial nerves. Motor examination was relevant for weakness of the neck flexors (Medical Research Council [MRC] 4+/5), the proximal pelvic muscles (MRC 3/5), and the shoulder muscles (MRC 4-/5). Distally, she performed much better (5-/5). Deep tendon reflexes were absent throughout. Sensory examination was normal, except for mild impairment of touch and pin sensation in both hands. She was unable to sit or stand independently.

An electrodiagnostic (EDX) examination was performed 3 days after admission and 6 days after the onset of neurologic symptoms. This was repeated later, on the 12th day after admission, which corresponded to day 15 from the onset of neurologic symptoms. Needle electromyography was not performed due to the acute nature of the symptoms.

Please now review the Nerve Conduction Studies tables.

EDX FINDINGS AND INTERPRETATION OF DATA

The first set of nerve conduction studies (NCS), performed on day 6 from the onset of neurologic symptoms, revealed the following:

The above findings point to pathology at the spinal roots and the peripheral sensory and motor nerves, manifesting as either axonal loss or distal conduction block (as a cause of low distal CMAPs). Only one criterion of demyelination (absent F waves) is fulfilled. The absent F waves and the sural sparing pattern (i.e., abnormal upper extremity SNAPs with normal sural SNAP) are findings that are highly suggestive of GBS (see discussion).

The second study, done 9 days later (15 days from the onset of neurologic symptoms), revealed that now all hand SNAPs (median, ulnar, and radial) are abnormally low in amplitude or absent. In contrast, the sural SNAP continues to be normal. The slowing of distal latencies now is more pronounced, which fulfills one of the criteria for acquired demyelination. The F waves are still absent, fulfilling a second criterion. However, the velocities are still moderately slowed and there is no confirmed conduction block. Thus, in the second study, two criteria of acquired demyelination are fulfilled (three are required; see discussion), and the sural sparing pattern (i.e., abnormal upper extremity SNAPs with normal sural SNAP) is confirmed. These findings are strong evidence for the diagnosis of GBS.

The prognosis here is fair because of low distal CMAPs, although at no time did the mean CMAP amplitude decrease below 20% of the lower limit of normal. The first study is less helpful because the patient had not reached plateau yet and because time for the completion of wallerian degeneration has not been allowed. The second study, done a week after the patient reached plateau, reveals a mean CMAP of 39% of the lower limit of normal.

In summary, the profile of these NCSs is consistent with an acquired demyelinating polyneuropathy as seen with acute inflammatory demyelinating polyneuropathy (AIDP), the most common type of GBS. The prognosis for recovery is fair due to modest decrease in mean CMAP amplitude. A repeat EMG 3 to 5 weeks after the onset of symptoms was recommended to confirm this prognostic prediction.

DISCUSSION

Adapted from Katirji B, Kaminski HJ, Preston DC et al., eds. Neuromuscular disorders in clinical practice. Boston, MA: Butterworth-Heinemann, 2002.

Certain clinical features and diagnostic studies are useful in establishing the correct diagnosis:

Clinical Features

Guillain-Barré syndrome (GBS), also known as Landry-Guillain-Barré-Strohl syndrome, is the most common cause of subacute flaccid paralysis in the world. It is a generalized disorder of the peripheral nervous system that is characterized by multiple limb and cranial muscle weakness with areflexia. It has an incidence of slightly less than 2 per 100 000 population. Guillain-Barré syndrome is frequently preceded by a viral or bacterial illness, usually an upper respiratory infection or gastroenteritis.

Typically, GBS develops over the course of a few days. Limb weakness appears simultaneously with a slight tingling and impairment of sensation in the hands and feet. The sensory symptoms are rarely painful while myalgia and back pain are common. Weakness usually ascends from the lower limbs to the upper limbs and, sometimes, to the cranial nerves. Less commonly, the weakness in GBS is descending. Facial weakness occurs in approximately one half of patients, and respiratory failure requiring mechanical ventilation occurs in one-third. Typically, progression lasts up to 4 weeks, while progression exceeding 4 weeks suggests an alternative diagnosis, such as chronic inflammatory demyelinating polyneuropathy (CIDP). Cerebrospinal fluid protein usually rises during the second week of illness, without pleocytosis (albuminocytologic dissociation). The presence of CSF pleocytosis is not incompatible with GBS, but if it is significant (>50 cells), other diagnoses, particularly infection with the human immunodeficiency virus (HIV), should be suspected. The frequency of various GBS manifestations is shown in Table C23-2.

Table C23-2 Frequency of Features and Clinical Variants of Acute Guillain-Barré Syndrome

Buy Membership for Neurology Category to continue reading. Learn more here
  Frequency (%)
Condition Initially In Fully Developed Illness
Features of Syndrome
Paresthesias 70 85
Weakness
Arms 20 90
Legs 60 95
Face 35 60
Oropharynx 25 50
Ophthalmoparesis 5 15
Sphincter dysfunction 15 5
Ataxia 10 15
Areflexia 75 90
Pain 25 30
Sensory loss 40 75
Respiratory failure 10 30
CSF protein >0.55 g/L 50 90
Abnormal electrophysiologic findings 95 99
Clinical variants*
Fisher syndrome   5
Weakness without paresthesias or sensory loss   3